| |
DCF, N = 37
|
bDCF, N = 22
|
p value
|
|---|
|
Age (years)a
|
61.2 ± 9.5
|
67.1 ± 7.3
|
0.016
|
|
Sex
| | |
0.725
|
|
Male/female
|
30/7
|
17/5
| |
|
Tumor locationb
| | |
0.045
|
|
Ut/Mt./Lt/Ae
|
5/21/10/1
|
2/10/4/6
| |
|
Clinical T stagec
| | |
0.502
|
|
T1/T2/T3/T4a/T4b
|
1/3/14/8/11
|
1/0/6/5/10
| |
|
Clinical N stagec
| | |
0.625
|
|
N0/N1/N2/N3
|
2/29/5/1
|
2/15/5/0
| |
|
Clinical M stagec
| | |
0.599
|
|
M0/M1 (LYM)
|
34/4
|
21/1
| |
|
Clinical stagec
| | |
0.151
|
|
IIA/IIB/IIIA/IIIB/IIIC/IV
|
1/3/20/2/8/3
|
1/0/7/1/12/1
| |
|
ASAPS
| | |
0.082
|
|
1/2/3
|
13/21/3
|
2/18/2
| |
|
Comorbidities
|
|
Heart disease
|
8
|
15
|
< 0.001
|
|
Pulmonary disease
|
1
|
4
|
0.039
|
|
Diabetes mellitus
|
5
|
5
|
0.362
|
- Ae abdominal esophagus, ASAPS American Society of Anesthesiologists performance states, Lt lower thoracic esophagus, LYM lymph node metastasis, Mt. middle thoracic esophagus, Ut upper thoracic esophagus
- aMean ± standard deviation
- bAccording to the Japanese Classification of Esophageal Cancer, 11th edition
- cAccording to the UICC classification, 7th edition
